Analysts Recommendations Adaptimmune Therapeutics plc(NASDAQ:ADAP): Bunge Limited(NYSE:BG)

0
5
touch screen graph on tablet

Adaptimmune Therapeutics plc (ADAP) will report its next earnings on Aug 06 BMO. The company reported the earnings of $-0.24/Share in the last quarter where the estimated EPS by analysts was $-0.25/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 4%.

Many analysts are providing their Estimated Earnings analysis for Adaptimmune Therapeutics plc and for the current quarter 3 analysts have projected that the stock could give an Average Earnings estimate of $-0.23/share. These analysts have also projected a Low Estimate of $-0.25/share and a High Estimate of $-0.23/share.

These analysts also forecasted Growth Estimates for the Current Quarter for ADAP to be 42.9%. They are projecting Next Quarter growth of 32.43%. For the next 5 years, Adaptimmune Therapeutics plc is expecting Growth of -8.94% per annum, whereas in the past 5 years the growth was 26.52% per annum.

The Relative Volume of the company is 0.19 and Average Volume (3 months) is 3.29 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -60.3%. The Return on Equity (ROE) value stands at -85.6%. While it’s Return on Investment (ROI) value is -113.3%.

While looking at the Stock’s Performance, Adaptimmune Therapeutics plc currently shows a Weekly Performance of -6.8%, where Monthly Performance is -6.01%, Quarterly performance is 152.41%, 6 Months performance is 125% and yearly performance percentage is 185.58%. Year to Date performance value (YTD perf) value is 642.5%. The Stock currently has a Weekly Volatility of 8.44% and Monthly Volatility of 7.78%.

Bunge Limited (BG) will report its next earnings on Jul 29 BMO. The company reported the earnings of $-1.34/Share in the last quarter where the estimated EPS by analysts was $0.67/share. The difference between the expected and actual EPS was $-2.01/share, which represents an Earnings surprise of -300%.

Many analysts are providing their Estimated Earnings analysis for Bunge Limited and for the current quarter 9 analysts have projected that the stock could give an Average Earnings estimate of $1.32/share. These analysts have also projected a Low Estimate of $1.01/share and a High Estimate of $1.59/share.

In case of Revenue Estimates, 7 analysts have provided their consensus Average Revenue Estimates for Bunge Limited as 9.7 Billion. According to these analysts, the Low Revenue Estimate for Bunge Limited is 8.47 Billion and the High Revenue Estimate is 10.2 Billion. The company had Year Ago Sales of 10.1 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for BG to be -13.8%. They are projecting Next Quarter growth of -10.64%. For the next 5 years, Bunge Limited is expecting Growth of 52.76% per annum, whereas in the past 5 years the growth was -42.58% per annum.

The Relative Volume of the company is 0.65 and Average Volume (3 months) is 1.53 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 10.97.

The company shows its Return on Assets (ROA) value of -8.2%. The Return on Equity (ROE) value stands at -33.3%. While it’s Return on Investment (ROI) value is -11%.

While looking at the Stock’s Performance, Bunge Limited currently shows a Weekly Performance of 3.99%, where Monthly Performance is 10.89%, Quarterly performance is 10.34%, 6 Months performance is -13.58% and yearly performance percentage is -21.17%. Year to Date performance value (YTD perf) value is -22.5%. The Stock currently has a Weekly Volatility of 3.02% and Monthly Volatility of 3.07%.

SHARE